Injection, Representational Image
Johannesburg : Chinese pharmaceutical company Sinovac Biotech on Friday launched the Phase III clinical trial of its Covid-19 vaccine on a group of children and teenagers between six months and 17 years old in South Africa.
The study, carried out in collaboration with South African company Numolux Group, has enrolled approximately 2,000 participants in the country, who will receive two doses of Sinovac’s CoronaVac vaccine or a placebo, 28 days apart. The efficacy assessment will be based on relevant indicators, the Xinhua news agency reported.
Numolux CEO Hilton Klein said that there are roughly 24 million children and teenagers in South Africa, and that if the vaccine made by Sinovac is approved for use on them, it will help the country reach herd immunity more quickly.
The South African Health Products Regulatory Authority authorised the use of the CoronaVac vaccine on the country’s adults in July.
Government says India has ample fuel stocks, stable supply, dismisses shortages and misinformation claims nationwide.
The flight landed at Kolkata Airport at around 12.45 a.m. It was supposed to take…
Who doesn’t want some extra cash? And if you can earn it just by sitting,…
At 66, most consider it an age of old age and retirement. However, this woman…
Elon Musk reveals SpaceX’s bold timeline: Starship aims to launch for Mars by 2026, with…
The researchers developed a novel hydrogel from biodegradable alginate, featuring a unique dual-network structure that…